Vivos Therapeutics, Inc. filed definitive additional proxy materials on November 20, 2026, reminding stockholders to cast their votes ahead of the company's 2026 Annual Meeting of Stockholders, scheduled for Wednesday, December 2, 2026, at 12:00 p.m. Eastern Time.
Key Highlights
- Meeting date: The 2026 Annual Meeting of Stockholders is set for Wednesday, December 2, 2026, at 12:00 p.m. Eastern Time.
- Filing type: The document is classified as Definitive Additional Materials under Schedule 14A.
- Proxy solicitor: Lioness Consulting LLC is acting as proxy solicitor for Vivos Therapeutics, Inc.
- No filing fee: The registrant indicated no fee was required for this filing.
- Stockholder outreach: The filing states that records indicate votes have not yet been received from certain stockholders as of the filing date.
Vivos Therapeutics Files Proxy Reminder Ahead of December Stockholder Meeting
Vivos Therapeutics, Inc. (NASDAQ:VVOS), a company focused on dental and orthodontic treatment technologies, submitted a proxy voting reminder to stockholders as part of its 2026 annual meeting solicitation process. The filing was submitted by the registrant and designated as Definitive Additional Materials under Schedule 14A, with no filing fee required, according to the document.
According to the filing, Lioness Consulting LLC, acting as proxy solicitor on behalf of Vivos Therapeutics, stated that its records indicated certain stockholders had not yet submitted their votes for the upcoming meeting. The filing directs stockholders to review the proxy statement, with a link to the full proxy statement document on file with the Securities and Exchange Commission provided in the materials. The meeting is scheduled to take place on Wednesday, December 2, 2026, beginning at 12:00 p.m. Eastern Time.
The filing does not detail the specific proposals to be voted on at the annual meeting, but directs stockholders to the previously filed definitive proxy statement for complete information. The solicitation is being conducted by Lioness Consulting LLC as the designated proxy solicitor for the registrant, and the materials were filed pursuant to Section 14(a) of the Securities Exchange Act of 1934.
What Was Disclosed
Vivos Therapeutics filed supplemental proxy materials reminding stockholders to vote before the December 2, 2026 annual meeting. The solicitation is managed by Lioness Consulting LLC, and stockholders were directed to the previously filed proxy statement for full meeting details.


Please wait processing your request...